Clinical Trial Update: The Effects of an NR2B NMDA Antagonist, CP-101,606, in Patients With Parkinson's Disease [Phase 2]

View source ↗

Summary

Pfizer-sponsored Phase 2 trial of the NR2B NMDA antagonist Traxoprodil (CP-101,606) in Parkinson's disease has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• Traxoprodil (CP-101,606)

Snippet

Sponsor: Pfizer | Conditions: Parkinson's Disease | Phase 2 | Status: COMPLETED